Recent Updates
Recently added Catalysts
MDAI Positive Sentiment

Spectral AI Schedules 2024 Third Quarter Financial Results and Conference Call

Key Takeaway: Spectral AI, Inc. announced it will release its financial results for the third quarter of 2024 on November 6, 2024, followed by a conference call at 5:00 pm Eastern Time. The company, based in Dallas, specializes in AI solutions for medical diagnostics, particularly in wound care. Their DeepView® System offers clinicians assessment capabilities for wound healing potential, aimed at enhancing patient outcomes and reducing healthcare costs. Investors are invited to join the live call or access the webcast via the company's Investor Relations page.
Price reaction · baseline $1.43 (2024-10-22 close) · hit after-hours · clean, no other MDAI news in the window
day 0 close
-10.5%
day 1 · peak
-11.2%
day 3
+7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Spectral AI is focused on revolutionizing wound care with its AI technology.
  • The upcoming financial results may indicate positive growth and developments.
  • DeepView® System aims to provide accurate assessments, potentially improving patient outcomes.

Full Press Release Details

DALLAS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2024 on Wednesday, November 6, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.
Investors interested in participating in the live call can dial:
412-317-1837 - International
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Frequently Asked Questions

When will Spectral AI announce its Q3 financial results?

Spectral AI will announce its Q3 financial results on November 6, 2024.

How can investors join Spectral AI's conference call?

Investors can join the call by dialing 412-317-1837 or via a webcast online.

What is the focus of Spectral AI's DeepView® System?

DeepView® System focuses on providing objective assessments of wound healing potential.

Where can I find more information about DeepView?

More information about DeepView can be found at www.spectral-ai.com.

What types of wounds does Spectral AI target?

Spectral AI targets wounds associated with burns and diabetic foot ulcers.

Last updated: Oct 23, 2024